Background: The androgen receptor (AR) plays a key role in hormone sensitive cancers, such as prostate cancer. Given the higher incidence of clear cell renal cell carcinoma (ccRCC) in men, AR involvement has been investigated in ccRCC, with controversial results. This study aimed to assess AR and pVHL expression in ccRCC, their associations with gender and clinicopathological features, and the prognostic value of AR expression. Methods: AR and pVHL expressions were retrospectively evaluated by immunohistochemistry (IHC) in ccRCC tumor samples from surgically treated patients (pts) at our Institution (2018-2024). Nuclear, cytoplasmic, and membranous staining were quantified using the H-score (0-300) and analyzed as continuous variables per 50 points increase. Associations with gender, IMDC risk score, T stage and WHO tumor grade (1-2 vs 3-4) were assessed using non-parametric tests and Spearman’s rank correlation, with Benjamini–Hochberg (BH) adjustment for multiple comparisons. Progression and survival were evaluated using Kaplan–Meier estimates and Cox proportional hazards models. Results: Fifty pts were enrolled (54% male; 68% grade G3-G4). No significant sex-related differences in AR and pVHL H-score were observed. Higher nuclear AR expression was associated with lower tumor grade (ρ=-0.591; 95% CI -0.735 to -0.402; p<0.001, qBH <0.001) as well as higher membrane pVHL expression with lower tumor grade (ρ=-0.435; -0.629 to -0.191; p=0.002, qBH =0.004). No significant association was observed between nuclear AR and membranous pVHL H-score. In the entire cohort, higher nuclear AR expression was significantly associated with longer OS (HR=0.393; 95% CI 0.197–0.785; p=0.029). Among 35 pts with localized disease at surgery, higher nuclear AR expression was associated with longer DFS in univariate (HR = 0.470; 0.271-0.815; p=0.029) and multivariate analysis adjusted for pT stage, grade, and sex (HR = 0.317; 0.140-0.718; p=0.006). Among 31 pts with de novo metastatic or relapsed disease, nuclear AR expression was lower than in 19 pts with localized disease without recurrence (p=0.005, rank-biserial = -0.479). In these 31 pts, nuclear AR H-score was not significantly associated with IMDC score, PFS (HR=0.848; 0.545-1.318; p=0.463) or OS (HR=0.629; 0.329-1.204; p=0.324). Conclusions: AR and pVHL expressions did not correlate with gender. Higher nuclear AR expression was associated with lower tumor grade, with longer DFS in patients with localized disease and with better OS in the entire cohort. In samples of metastatic patients, AR expression was lower compared to those of patients without relapses and not associated with PFS or OS. These findings support further investigation on AR, pVHL and other interactors in the biology of ccRCC.

Background: The androgen receptor (AR) plays a key role in hormone sensitive cancers, such as prostate cancer. Given the higher incidence of clear cell renal cell carcinoma (ccRCC) in men, AR involvement has been investigated in ccRCC, with controversial results. This study aimed to assess AR and pVHL expression in ccRCC, their associations with gender and clinicopathological features, and the prognostic value of AR expression. Methods: AR and pVHL expressions were retrospectively evaluated by immunohistochemistry (IHC) in ccRCC tumor samples from surgically treated patients (pts) at our Institution (2018-2024). Nuclear, cytoplasmic, and membranous staining were quantified using the H-score (0-300) and analyzed as continuous variables per 50 points increase. Associations with gender, IMDC risk score, T stage and WHO tumor grade (1-2 vs 3-4) were assessed using non-parametric tests and Spearman’s rank correlation, with Benjamini–Hochberg (BH) adjustment for multiple comparisons. Progression and survival were evaluated using Kaplan–Meier estimates and Cox proportional hazards models. Results: Fifty pts were enrolled (54% male; 68% grade G3-G4). No significant sex-related differences in AR and pVHL H-score were observed. Higher nuclear AR expression was associated with lower tumor grade (ρ=-0.591; 95% CI -0.735 to -0.402; p<0.001, qBH <0.001) as well as higher membrane pVHL expression with lower tumor grade (ρ=-0.435; -0.629 to -0.191; p=0.002, qBH =0.004). No significant association was observed between nuclear AR and membranous pVHL H-score. In the entire cohort, higher nuclear AR expression was significantly associated with longer OS (HR=0.393; 95% CI 0.197–0.785; p=0.029). Among 35 pts with localized disease at surgery, higher nuclear AR expression was associated with longer DFS in univariate (HR = 0.470; 0.271-0.815; p=0.029) and multivariate analysis adjusted for pT stage, grade, and sex (HR = 0.317; 0.140-0.718; p=0.006). Among 31 pts with de novo metastatic or relapsed disease, nuclear AR expression was lower than in 19 pts with localized disease without recurrence (p=0.005, rank-biserial = -0.479). In these 31 pts, nuclear AR H-score was not significantly associated with IMDC score, PFS (HR=0.848; 0.545-1.318; p=0.463) or OS (HR=0.629; 0.329-1.204; p=0.324). Conclusions: AR and pVHL expressions did not correlate with gender. Higher nuclear AR expression was associated with lower tumor grade, with longer DFS in patients with localized disease and with better OS in the entire cohort. In samples of metastatic patients, AR expression was lower compared to those of patients without relapses and not associated with PFS or OS. These findings support further investigation on AR, pVHL and other interactors in the biology of ccRCC.

RetrOspective study of anDrogen rEceptor expressiOn in clear cell renal carcinoma (RODEO)

PITTARELLO, CHIARA
2024/2025

Abstract

Background: The androgen receptor (AR) plays a key role in hormone sensitive cancers, such as prostate cancer. Given the higher incidence of clear cell renal cell carcinoma (ccRCC) in men, AR involvement has been investigated in ccRCC, with controversial results. This study aimed to assess AR and pVHL expression in ccRCC, their associations with gender and clinicopathological features, and the prognostic value of AR expression. Methods: AR and pVHL expressions were retrospectively evaluated by immunohistochemistry (IHC) in ccRCC tumor samples from surgically treated patients (pts) at our Institution (2018-2024). Nuclear, cytoplasmic, and membranous staining were quantified using the H-score (0-300) and analyzed as continuous variables per 50 points increase. Associations with gender, IMDC risk score, T stage and WHO tumor grade (1-2 vs 3-4) were assessed using non-parametric tests and Spearman’s rank correlation, with Benjamini–Hochberg (BH) adjustment for multiple comparisons. Progression and survival were evaluated using Kaplan–Meier estimates and Cox proportional hazards models. Results: Fifty pts were enrolled (54% male; 68% grade G3-G4). No significant sex-related differences in AR and pVHL H-score were observed. Higher nuclear AR expression was associated with lower tumor grade (ρ=-0.591; 95% CI -0.735 to -0.402; p<0.001, qBH <0.001) as well as higher membrane pVHL expression with lower tumor grade (ρ=-0.435; -0.629 to -0.191; p=0.002, qBH =0.004). No significant association was observed between nuclear AR and membranous pVHL H-score. In the entire cohort, higher nuclear AR expression was significantly associated with longer OS (HR=0.393; 95% CI 0.197–0.785; p=0.029). Among 35 pts with localized disease at surgery, higher nuclear AR expression was associated with longer DFS in univariate (HR = 0.470; 0.271-0.815; p=0.029) and multivariate analysis adjusted for pT stage, grade, and sex (HR = 0.317; 0.140-0.718; p=0.006). Among 31 pts with de novo metastatic or relapsed disease, nuclear AR expression was lower than in 19 pts with localized disease without recurrence (p=0.005, rank-biserial = -0.479). In these 31 pts, nuclear AR H-score was not significantly associated with IMDC score, PFS (HR=0.848; 0.545-1.318; p=0.463) or OS (HR=0.629; 0.329-1.204; p=0.324). Conclusions: AR and pVHL expressions did not correlate with gender. Higher nuclear AR expression was associated with lower tumor grade, with longer DFS in patients with localized disease and with better OS in the entire cohort. In samples of metastatic patients, AR expression was lower compared to those of patients without relapses and not associated with PFS or OS. These findings support further investigation on AR, pVHL and other interactors in the biology of ccRCC.
2024
RetrOspective study of anDrogen rEceptor expressiOn in clear cell renal carcinoma (RODEO)
Background: The androgen receptor (AR) plays a key role in hormone sensitive cancers, such as prostate cancer. Given the higher incidence of clear cell renal cell carcinoma (ccRCC) in men, AR involvement has been investigated in ccRCC, with controversial results. This study aimed to assess AR and pVHL expression in ccRCC, their associations with gender and clinicopathological features, and the prognostic value of AR expression. Methods: AR and pVHL expressions were retrospectively evaluated by immunohistochemistry (IHC) in ccRCC tumor samples from surgically treated patients (pts) at our Institution (2018-2024). Nuclear, cytoplasmic, and membranous staining were quantified using the H-score (0-300) and analyzed as continuous variables per 50 points increase. Associations with gender, IMDC risk score, T stage and WHO tumor grade (1-2 vs 3-4) were assessed using non-parametric tests and Spearman’s rank correlation, with Benjamini–Hochberg (BH) adjustment for multiple comparisons. Progression and survival were evaluated using Kaplan–Meier estimates and Cox proportional hazards models. Results: Fifty pts were enrolled (54% male; 68% grade G3-G4). No significant sex-related differences in AR and pVHL H-score were observed. Higher nuclear AR expression was associated with lower tumor grade (ρ=-0.591; 95% CI -0.735 to -0.402; p<0.001, qBH <0.001) as well as higher membrane pVHL expression with lower tumor grade (ρ=-0.435; -0.629 to -0.191; p=0.002, qBH =0.004). No significant association was observed between nuclear AR and membranous pVHL H-score. In the entire cohort, higher nuclear AR expression was significantly associated with longer OS (HR=0.393; 95% CI 0.197–0.785; p=0.029). Among 35 pts with localized disease at surgery, higher nuclear AR expression was associated with longer DFS in univariate (HR = 0.470; 0.271-0.815; p=0.029) and multivariate analysis adjusted for pT stage, grade, and sex (HR = 0.317; 0.140-0.718; p=0.006). Among 31 pts with de novo metastatic or relapsed disease, nuclear AR expression was lower than in 19 pts with localized disease without recurrence (p=0.005, rank-biserial = -0.479). In these 31 pts, nuclear AR H-score was not significantly associated with IMDC score, PFS (HR=0.848; 0.545-1.318; p=0.463) or OS (HR=0.629; 0.329-1.204; p=0.324). Conclusions: AR and pVHL expressions did not correlate with gender. Higher nuclear AR expression was associated with lower tumor grade, with longer DFS in patients with localized disease and with better OS in the entire cohort. In samples of metastatic patients, AR expression was lower compared to those of patients without relapses and not associated with PFS or OS. These findings support further investigation on AR, pVHL and other interactors in the biology of ccRCC.
Renal cell carcinoma
Androgen Receptor
VHL
Clear cell RCC
File in questo prodotto:
File Dimensione Formato  
Pittarello_Chiara.pdf

Accesso riservato

Dimensione 2.83 MB
Formato Adobe PDF
2.83 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/119678